Enrich Therapeutics Inc. a biotech company focusing on unique microfluidics-free cell discovery and isolation technology, announced today that the company had been awarded a 12-month Small Business Innovation Research (SBIR) research contract from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), for further development of this critical application on cell/tissue sample processing with its proprietary cell isolation technology. This project will be performed in collaboration with Dr. Kien Pham’s team from Yale Pathology Dept.
Single cell multimodal omics (scMulti-omics) technologies by integrating different readouts, such as DNA, RNA and protein expression, can provide greater value than the sum of the parts making these technologies powerful to characterize the cell in-depth. Isolation of unique cell populations, and simultaneous and selective extraction of different macromolecules can enable further experimental analyses to answer critical questions in basic science and clinical research and empower observational and therapeutic studies. By 2025, the global scMulti-omics market is anticipated to be $5.32 billion, mainly driven by the increasing need for noninvasive or minimally invasive diagnosis and personalized medicine.
Recent advances have significantly improved multi-omic analysis; however, the sample processing technologies for tumors, in particular solid tumors for multi-omic analysis, are lagging behind. The existing technologies are associated with low throughput, high cost, and sub-optimal processing affecting data quality, which hampers their widespread use in biology and ultimately in medicine. There is a need for robust sample processing technologies that are compatible with downstream analysis and can be easily integrated into the preanalytical workflow.
With this financial support from NCI, Enrich expects to provide a robust sample processing platform that could easily integrate with scMulti-omic analysis and allow a better understanding of heterogeneity in solid tumors and the microenvironment, and also enable the analysis of rare and low-abundant cells such as circulating tumor cells and antigen-presenting cells, to potentially open the door to new biomarker and therapeutic targets discoveries in cancer. development of technologies to improve single-cell multi-omic preanalytical microfluidic platforms that integrate steps of the preanalytical workflow such as sample processing, single-cell separation or isolation and enrichment, technologies for solid tumor dissociation/isolation, enrichment and tracking of cancer cells and/or biomolecules for scMulti-omics.
The research reported in this publication is supported by the National Cancer Institute, part of the National Institutes of Health, under research topic number NIH/NCI 439. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
About this contract
The total amount of this contract is $ 399,761.00.
100% project cost will be financed with Federal funds.
This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N91022C00061.
Enrich Therapeutics will be introducing our brand new TROVO system, a novel microfluidics-free cell discovery and isolation platform, at the 7th annual CAR-TCR Summit. Come to see us at booth D70 and find out how Enrich technology enables discovering meaningful clones.
Annual CAR-TCR Summit is the biggest CAR-TCR meeting around the world, uniting experts from the long-standing commercial giants to the trailblazing pioneers, and discover new strategies for everything from discovery to early phase development to commercialization.
MassChallenge has officially named the 2022 cohort for the US early-stage program, and Enrich Therapeutics Inc. is pleased to be one of them! We look forward to all we will gain throughout this program, and we’re excited to tap into the @MassChallenge global network of world-class mentors and partners.
MassChallenge is the global network for innovators. It supports entrepreneurs and startups through the early stages of building a business. Founded in 2009, MassChallenge’s mission is to equip bold entrepreneurs to disrupt the status quo and create sustainable change.
Through MassChallenge’s global network, entrepreneurs get access to industry-based mentors and resources to support every area of the startup lifecycle so they can help solve some of the world’s most massive challenges. MassChallenge’s hyper-focused, proven methodology helps founders identify goals and key initiatives, providing access to a meaningful network of experts and mentors, while also providing connection to a deep peer network from across the global community.
BioTools Innovator, a new program run by MedTech Innovator, with a focus on accelerating life science tools and diagnostics, just announced the ten companies selected to participate in the organization’s inaugural three-month virtual mentorship-focused Accelerator program.
BioTools Innovator works closely with stakeholders across the industry to foster the growth of early to mid-stage startups. The top ten leading-edge biotechnology startups are developing solutions for cell research, genomics, data and informatics, and synthetic biology and hail from across the U.S. and Europe.
Enrich Therapeutics Inc. is honored to be chosen by BioTools Innovator as one of the top 10 leading biotech startups developing solutions to advance research & improve human health! The company looks forward to participating in the inaugural 2021 Accelerator program.
Enrich Therapeutics Inc. announced today that the company is going to present at the 2021 CYTO Innovation Showcase live on Tuesday, June 8, 2021. Enrich cell isolation technology was selected as one of the three technology showcase finalists after being qualified through vigorous competition. The CYTO Virtual Interactive 2021 conference hosts by ISAC (the International Society for the Advancement of Cytometry) on June 7-10, 2021.
Enrich Therapeutics Inc. announced today that the company signed a lease for 5,500 square feet of independent lab and office space in Business Park of Branford, CT. It is currently setting up its new operation space and will be completely moving out of BioCT Incubator in Groton by the end of this month. This new expansion would greatly benefit the company’s team building, business operation, collaborating R&D projects, as well as investor relationships.
Enrich Therapeutics Inc., a device and application company focusing on unique single cell isolation technology, announced today that the company has been awarded a 24-month Small Business Innovation Research (SBIR) phase II grant in the amount of $1.7 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for further development of its proprietary single cell isolation platform.
Characterizing both functional and genetic heterogeneity among a pool of cells remains a major scientific challenge in immunology, cancer research, neurobiology, and developmental biology. Isolating cells with the same phenotype is the key to understanding such heterogeneity. Enrich proprietary technology targets the huge cell isolation market valued at more than $6B in 2020, and can be used to select and isolate cells based on organelle translocation, chromatin morphology, phagocytosis, synapse formation, protein co-localization, cell-cell interactions and other time-resolved cellular behaviors which cannot be achieved by current sorting platforms in a high-throughput manner.
During SBIR phase I of this project, which the grant was awarded within 10 months since the inception of Enrich Therapeutics, the company has established a unique, non-fluidic, technology to address the aforementioned unmet needs. The Enrich team completed the alpha version of prototype design and demonstrated its utility in critical POC applications, such as blood cell removal, phage enrichment on single beads, and isolation of tumor-killing immune cell clones. All phase I milestones were fully accomplished with convincing results, and the new award is intended to facilitate the translation of this promising technology to a commercial product and ultimately provide beneficial life science innovation to global biomedical researchers.
This new grant follows the company’s successful Phase I findings and will support the ongoing work of platform optimization and product development. Enrich team is tirelessly continuing the effort to bring its technology to market, besides the device, the company is planning to launch two accompanying application kits, Enrich-Live and Enrich-Seq, to unify the fragmented cell isolation market. The successful commercialization of Enrich products will enable thousands of cell biology labs and clinical settings to manipulate single cells as well as desired cell combinations on their computer screens with much-reduced cost and superior outcome.
The research reported in this publication was supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, under Award Number R44AI147734. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Enrich therapeutics Inc. (founded in 2018), a device and application company focusing in unique single cell isolation technology, announced today that it successfully closed $320k in seed funding. The round was led by Connecticut Innovations, with participation from other angel investors in Boston Harbor Angels and Teich Technology Investments. This fund will support the ongoing development of Enrich’s proprietary single cell isolation platform.
Enrich Therapeutics develops NIAID funded novel single cell isolation platform to enhance global biomedical research at true single cell level with superior affordability and strength. Its static cell capture technology enables clone isolation under desired micro-environment with real-time monitoring. Enrich platform will have extensive impact in fields of basic biology, CAR-T, antibody, tumor genetics etc. Enrich team is committed to isolating single clones from any physiologically relevant scenario.
Enrich Therapeutics set up its new operating location and application development laboratory in BioCT Innovation Commons started on July 2019. This new expansion would greatly benefit our business operation, investor relationship as well as collaborating R&D projects.
Enrich Therapeutics has been awarded a Small Business Innovation Research (SBIR) phase 1 grant from National Institute of Health (NIH) in June 2019. The award will support our expedited development of disruptive single cell isolation platform as well as integrated novel applications.